Lexicon Pharmaceuticals, Inc. (LXRX)

NASDAQ: LXRX · IEX Real-Time Price · USD
2.42
+0.09 (3.86%)
Sep 27, 2022 4:00 PM EDT - Market closed
3.86%
Market Cap 456.72M
Revenue (ttm) 109,000
Net Income (ttm) -96.80M
Shares Out 188.73M
EPS (ttm) -0.61
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 513,458
Open 2.36
Previous Close 2.33
Day's Range 2.35 - 2.44
52-Week Range 1.31 - 6.33
Beta 1.43
Analysts Buy
Price Target 13.26 (+447.9%)
Earnings Date Nov 1, 2022

About LXRX

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentec... [Read more...]

Industry Biotechnology
IPO Date Apr 7, 2000
Employees 87
Stock Exchange NASDAQ
Ticker Symbol LXRX
Full Company Profile

Financial Performance

In 2021, LXRX's revenue was $298,000, a decrease of -98.76% compared to the previous year's $24.00 million. Losses were -$87.76 million, 49.8% more than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for LXRX stock is "Buy." The 12-month stock price forecast is 13.26, which is an increase of 447.93% from the latest price.

Price Target
$13.26
(447.93% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Lexicon Pharmaceuticals Highlights Scientific and Medical Presentations Relating to Its Successful Phase 2 Proof-Of-C...

Poster and Oral Presentation at PAINWeek Describing a Novel Mechanism of Action for Neuropathic Pain

1 week ago - GlobeNewsWire

Lexicon Pharmaceuticals Highlights Publications Relating to Sotagliflozin's Differentiated Dual SGLT1 and SGLT2 Mecha...

Results to be Presented at the European Society for Cardiology Congress Demonstrate Differential Effects During Endothelial Dysfunction in Cell Studies

1 month ago - GlobeNewsWire

Lexicon Announces Full Exercise and Closing of Options to Purchase Additional Shares in Connection with Previously An...

THE WOODLANDS, Texas, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced the issuance and sale of an additional 2,526,540 shares of its common s...

1 month ago - GlobeNewsWire

Lexicon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Sotagliflozin New Drug Application for Heart Failure Accepted for Review by FDA, with PDUFA Action Date Anticipated in May 2023

1 month ago - GlobeNewsWire

Lexicon Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 2, 2022

THE WOODLANDS, Texas, July 29, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its second quarter 2022 financial results on Tuesday, August 2, 2022 after the markets ...

1 month ago - GlobeNewsWire

Lexicon Announces Proposed Public Offering Of Common Stock

THE WOODLANDS, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced that it has commenced an underwritten public offering to offer and sell...

2 months ago - GlobeNewsWire

Lexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure

NDA supported by SOLOIST-WHF and SCORED Global Phase 3 Program Evaluating Sotagliflozin in Almost 12,000 People NDA supported by SOLOIST-WHF and SCORED Global Phase 3 Program Evaluating Sotagliflozin in...

2 months ago - GlobeNewsWire

Lexicon Announces Positive Top-Line Results From Phase 2 Proof-Of-Concept Study Of LX9211 In Painful Diabetic Neuropathy

Study Supports Translation of Potential New Mechanism of Action for Neuropathic Pain and Advancement of LX9211 Development in Painful Diabetic Neuropathy

2 months ago - GlobeNewsWire

Lexicon Pharmaceuticals to Participate in the Jefferies 2022 Healthcare Conference

THE WOODLANDS, Texas, June 01, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicon's chief executive officer, will present at the Jefferies 2...

3 months ago - GlobeNewsWire

Lexicon Resubmits New Drug Application for Sotagliflozin for the Treatment of Heart Failure

THE WOODLANDS, Texas, May 31, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Adminis...

3 months ago - GlobeNewsWire

7 Biotech Stocks With Key Catalysts for May

The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns. The post 7 Biotech Stocks With Key Catalysts for May appeared first on InvestorP...

4 months ago - InvestorPlace

Lexicon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical Update

Conference Call and Webcast at 8:00 am Eastern Time Conference Call and Webcast at 8:00 am Eastern Time

4 months ago - GlobeNewsWire

Lexicon Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 5, 2022

THE WOODLANDS, Texas, April 29, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its first quarter 2022 financial results on Thursday, May 5, 2022 before the markets o...

4 months ago - GlobeNewsWire

Sotagliflozin Improved Outcomes in Patients With and Without Prior Cardiovascular Disease in New Analysis Presented a...

Late-breaking presentation of analysis of SCORED clinical trial data describes significant reduction in cardiovascular death, myocardial infarction and stroke with sotagliflozin treatment as compared to...

5 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lexicon Pharmaceuticals, Inc. - LXRX

NEW YORK , March 26, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Lexicon Pharmaceuticals, Inc. ("Lexicon" or the "Company") (NASDAQ: LXRX).  Such investors are a...

6 months ago - PRNewsWire

New Analysis of Cardiovascular Endpoints in the SCORED Trial to Be Presented at the American College of Cardiology's ...

Late-breaking clinical trial presentation by Deepak L. Bhatt, M.D., M.P.H., will describe new analysis of rates of CV death, myocardial infarction and stroke in the SCORED trial Late-breaking clinical t...

6 months ago - GlobeNewsWire

Lexicon Enters Into Loan Facility With Oxford Finance for Up to $150 Million to Support Planned Commercialization of ...

THE WOODLANDS, Texas, March 17, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it entered into a loan facility with Oxford Finance LLC that provides up to $150 mil...

6 months ago - GlobeNewsWire

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Lexicon Pharmaceuticals,...

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Lexicon Pharmaceuti...

6 months ago - Business Wire

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Lexicon Pharmaceuticals, Inc. (LXRX) on Beh...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Lexicon Pharmaceuticals, Inc. (“Lexicon” or the “Company”) (NASDAQ: LXRX) investors concerning the ...

6 months ago - Business Wire

The Law Offices of Frank R. Cruz Announces Investigation of Lexicon Pharmaceuticals, Inc. (LXRX) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Lexicon Pharmaceuticals, Inc. (“Lexicon” or the “Company”) (NASDAQ: LXRX) on behalf of investors concerning t...

6 months ago - Business Wire

Why Lexicon Pharmaceuticals Was Plunging on Monday

The shares are reeling from disquieting news about the company's leading pipeline drug.

6 months ago - The Motley Fool

Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Clinical Update

Conference Call and Webcast at 8:00 am Eastern Time Conference Call and Webcast at 8:00 am Eastern Time

6 months ago - GlobeNewsWire

Lexicon Voluntarily Withdraws Sotagliflozin New Drug Application and Plans Prompt Resubmission Targeted Early Q2 2022

Resubmission to Correct Recently-Identified Technical Issue

6 months ago - GlobeNewsWire

Lexicon Pharma Pulls Sotagliflozin US Application Due To Technical Issue, Shares Fall

Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) has voluntarily withdrawn and planned near-term resubmission of the sotagliflozin U.S. application to correct a technical issue with the submission recently id...

6 months ago - Benzinga

Lexicon Pharmaceuticals to Host Fourth Quarter 2021 Financial Results Conference Call and Webcast on February 28, 2022

THE WOODLANDS, Texas, Feb. 25, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter 2021 financial results on Monday, February 28, 2022 before the mark...

7 months ago - GlobeNewsWire